ResMed, Inc. (NYSE: RMD) reported Q4 EPS of $0.64, $0.02 worse than the analyst estimate of $0.66. Revenue for the quarter came in at $415.2 million versus the consensus estimate of $433.42 million.

For earnings history and earnings-related data on ResMed, Inc. (RMD) click here.